Nanomaterials and Innate Immunity: A Perspective of the Current Status in Nanosafety.


Journal

Chemical research in toxicology
ISSN: 1520-5010
Titre abrégé: Chem Res Toxicol
Pays: United States
ID NLM: 8807448

Informations de publication

Date de publication:
18 05 2020
Historique:
pubmed: 21 4 2020
medline: 3 7 2021
entrez: 21 4 2020
Statut: ppublish

Résumé

Human exposure to engineered nanomaterials (ENMs) is inevitable due to the plethora of applications for which they are being manufactured and integrated within. ENMs demonstrate plentiful advantages in terms of industrial approaches as well as from a consumer perspective. However, despite such positives, doubts remain over the human health implications of ENM exposure. In light of the increased research focus upon the potential effects of ENM exposure to human health in recent decades, questions still remain regarding the safety of these highly advanced, precision-tuned physical entities. The risk of short-term, high-dose exposure to humans is considered relatively low, although this has formed the direction of the hazard-assessment community since the turn of the 21st century. However, the possibility of humans being exposed repeatedly over a long period of time to a low-dose of ENMs of varying physicochemical characteristics is of significant concern, and thus, industry, government, academic, and consumer agencies are only now beginning to consider this. Notably, when considering the human health implications of such low-dose, long-term, repeated exposure scenarios, the impact of ENMs upon the human immune system is of primary importance. However, there remains a real need to understand the impact of ENMs upon the human immune system, especially the innate immune system, at all stages of life, given exposure to nanosized particles begins before birth, that is, of the fetus. Therefore, the purpose of this perspective is to summarize what is currently known regarding ENM exposure of different components of the innate immune system and identify knowledge gaps that should be addressed if we are to fully deduce the impact of ENM exposure on innate immune function.

Identifiants

pubmed: 32307980
doi: 10.1021/acs.chemrestox.0c00051
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1061-1073

Auteurs

James G Cronin (JG)

Immunometabolism & Cancer Research Group, Institute of Life Science, Swansea University Medical School, Swansea, Wales SA2 8PP, U.K.

Nicholas Jones (N)

Human Immunology Research Group, Institute of Life Science, Swansea University Medical School, Swansea, Wales SA2 8PP, U.K.

Catherine A Thornton (CA)

Human Immunology Research Group, Institute of Life Science, Swansea University Medical School, Swansea, Wales SA2 8PP, U.K.

Gareth J S Jenkins (GJS)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Swansea, Wales SA2 8PP, U.K.

Shareen H Doak (SH)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Swansea, Wales SA2 8PP, U.K.

Martin J D Clift (MJD)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Swansea, Wales SA2 8PP, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH